| Abstrakt: |
A study conducted at Soochow University in Suzhou, China, explores the use of engineered bacteria as a targeted therapeutic delivery system for cancer treatment. The researchers developed a bacterial biohybrid called E. coli-pE@PCN, which combines genetically engineered Escherichia coli with nano-sonosensitizers for enhanced and targeted sonodynamic therapy (SDT). The study found that E. coli-pE@PCN-based SDT effectively inhibited the growth of colorectal tumors and induced potent antitumor immune responses. The research suggests that this programmable bacteria-based biohybrid could pave the way for next-generation sonodynamic-immunotherapeutics to eliminate cancer and prevent its relapse and metastasis. [Extracted from the article] |
